Improved outcome for patients with relapsed/refractory mantle cell lymphoma (MCL) who stop ibrutinib +/− rituximab for reasons other than progression of disease. (June 2017) - Chen, W.; Zeng, D.; Desai, A.; Badillo, M.; Feng, L.; Yan, F.; Nomie, K.; Ping, L.; Ye, H.; Liang, Y.; Lee, H.; Oki, Y.; et al.